These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Development of a multifunctional detoxifying unit for liver failure patients. Lee K; Mun CH; Min BG Blood Purif; 2012; 34(3-4):225-30. PubMed ID: 23171622 [TBL] [Abstract][Full Text] [Related]
7. Albumin regeneration in liver support-comparison of different methods. Mitzner S; Klammt S; Stange J; Schmidt R Ther Apher Dial; 2006 Apr; 10(2):108-17. PubMed ID: 16684211 [TBL] [Abstract][Full Text] [Related]
8. Sorbent-based artificial liver devices: principles of operation, chemical effects and clinical results. Carpentier B; Ash SR Expert Rev Med Devices; 2007 Nov; 4(6):839-61. PubMed ID: 18035950 [TBL] [Abstract][Full Text] [Related]
9. Prometheus versus molecular adsorbents recirculating system: comparison of efficiency in two different liver detoxification devices. Evenepoel P; Laleman W; Wilmer A; Claes K; Kuypers D; Bammens B; Nevens F; Vanrenterghem Y Artif Organs; 2006 Apr; 30(4):276-84. PubMed ID: 16643386 [TBL] [Abstract][Full Text] [Related]
10. Powdered sorbent liver dialysis and pheresis in treatment of hepatic failure. Ash SR Ther Apher; 2001 Oct; 5(5):404-16. PubMed ID: 11778927 [TBL] [Abstract][Full Text] [Related]
11. Molecular adsorbent recirculating system treatment for patients with liver failure: the Hong Kong experience. Chiu A; Chan LM; Fan ST Liver Int; 2006 Aug; 26(6):695-702. PubMed ID: 16842326 [TBL] [Abstract][Full Text] [Related]
12. Emerging indications for albumin dialysis. Sen S; Williams R; Jalan R Am J Gastroenterol; 2005 Feb; 100(2):468-75. PubMed ID: 15667509 [TBL] [Abstract][Full Text] [Related]
13. Pro-inflammatory interleukin-18 and Caspase-1 serum levels in liver failure are unaffected by MARS treatment. Roth GA; Faybik P; Hetz H; Hacker S; Ankersmit HJ; Bacher A; Thalhammer T; Krenn CG Dig Liver Dis; 2009 Jun; 41(6):417-23. PubMed ID: 19019743 [TBL] [Abstract][Full Text] [Related]
14. How can liver toxins be removed? Filtration and adsorption with the Prometheus system. Vienken J; Christmann H Ther Apher Dial; 2006 Apr; 10(2):125-31. PubMed ID: 16684213 [TBL] [Abstract][Full Text] [Related]
15. Sorbents in treatment of uremia: a short history and a great future. Ash SR Semin Dial; 2009; 22(6):615-22. PubMed ID: 20017831 [TBL] [Abstract][Full Text] [Related]
17. Clearing of toxic substances: are there differences between the available liver support devices? Krisper P; Stadlbauer V; Stauber RE Liver Int; 2011 Sep; 31 Suppl 3():5-8. PubMed ID: 21824275 [TBL] [Abstract][Full Text] [Related]
18. Fluidized bed adsorbent systems for extracorporeal liver support. Falkenhagen D; Brandl M; Hartmann J; Kellner KH; Posnicek T; Weber V Ther Apher Dial; 2006 Apr; 10(2):154-9. PubMed ID: 16684217 [TBL] [Abstract][Full Text] [Related]
19. [Prospectives for using the extracorporeal connection of a xenospleen in treating patients with liver cirrhosis and obstructive jaundice complicated by liver failure]. Vakhidov AV; Kasymov ShZ; Kirichenko IP; Nazyrov FG; Kornienko VI; Akbarov MM Vestn Khir Im I I Grek; 1993; 150(1-2):90-2. PubMed ID: 7701715 [TBL] [Abstract][Full Text] [Related]
20. Experience of Mars therapy with and without transplantation in 101 patients with liver insufficiency. Koivusalo AM; Vakkuri A; Höckerstedt K; Isoniemi H Transplant Proc; 2005 Oct; 37(8):3315-7. PubMed ID: 16298584 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]